Abstract

Hydroxychloroquine Sulfate 25 mg/mL in Ora-Plus:Ora-Sweet SF

Author(s): Allen Loyd V Jr

Issue: Jul/Aug 2020 - Volume 24, Number 4

Page(s): 316

Download in electronic PDF format for $75
  • Hydroxychloroquine Sulfate 25 mg/mL in Ora-Plus:Ora-Sweet SF Page 1

Abstract

A formulation for preparing Hydroxychloroquine Sulfate 25 mg/mL in Ora-Plus:Ora-Sweet SF. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • formulation
  • hydroxychloroquine sulfate
  • antimalarial agent
  • malaria
  • lupus erythematosus
  • antirheumatic agent
  • rheumatic diseases
  • rheumatoid arthritis
  • COVID-19 pandemic
  • coronavirus
  • SARS-CoV-2

Related Categories

  • FORMULATIONS
  • ALLERGY/IMMUNOLOGY/INFLAMMATION
  • INFECTIOUS DISEASE
  • MUSCULOSKELETAL DISORDERS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2020
Pg. 316
Hydroxychloroquine Sulfate 25 mg/mL in Ora-Plus:Ora-Sweet SF
Author(s): Allen Loyd V Jr
Nov/Dec 2017
Pg. 494
Hydroxychloroquine Sulfate 25 mg/mL in Oral Mix or Oral Mix SF
Author(s): Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312
Wetting and/or Solubilizing Agents, Featured Excipient:
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 287-295
Pharmacies on the Frontline: Responding to the COVID-19 Pandemic
Author(s): McElhiney Linda F
May/Jun 2023
Pg. 192-200
Compounding for the Treatment of COVID-19 and Long COVID, Part 3: The Role of Toll-like Receptors in SARS-CoV-2 Infection and COVID Development
Author(s): Riepl Mike, Kaiser Joe
Jan/Feb 2015
Pg. 66
Hydroxychloroquine Sulfate 200-mg Capsules
Author(s): Allen Loyd V Jr
May/Jun 2017
Pg. 251-254
Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes
Author(s): McHenry Adam R, Wempe Michael F, Rice Peter J
Jan/Feb 2023
Pg. 12-21
Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants
Author(s): Riepl Mike
Mar/Apr 2021
Pg. 144
Eslicarbazepine Acetate 40-mg/mL in Ora-Plus with Ora-Sweet or Ora-Sweet SF Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2023
Pg. 284-293
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID
Author(s): Riepl Mike, Kaiser Joe
Sep/Oct 2023
Pg. 368-380
Compounding for the Treatment of COVID-19 and Long COVID, Part 5: Associated Conditions, Prophylaxis, and Effective Treatment
Author(s): Riepl Mike, Kaiser Joe
Mar/Apr 2023
Pg. 98-107
Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment
Author(s): Riepl Mike
Jul/Aug 2020
Pg. 268
PreScription: COVID-19 and Compounding Pharmacists
Author(s): Allen Loyd V Jr
Sep/Oct 2019
Pg. 413
Verapamil Hydrochloride 50 mg/mL in Ora-Plus:Ora-Sweet (1:1)
Author(s): Allen Loyd V Jr
Nov/Dec 2018
Pg. 496
Hydroxyurea 100 mg/mL in Ora-Plus:Ora-Sweet, Ora-Plus: Ora-Sweet SF, Ora-Blend or Oral-Blend SF Oral Suspensions
Author(s): Allen Loyd V Jr
Jan/Feb 2019
Pg. 57
Minoxidil 1-mg/mL in Ora-Plus and Ora-Sweet SF Suspension
Author(s): Allen Loyd V Jr
Jan/Feb 2023
Pg. 53
Erlotinib 10 mg/mL in Ora-Sweet and Ora-Plus
Author(s): Allen Loyd V Jr
Jan/Feb 2018
Pg. 51
Mercaptopurine 50 mg/mL in Ora-Sweet and Ora-Plus Suspension
Author(s): Allen Loyd V Jr
Jan/Feb 2018
Pg. 58
Thalidomide 20 mg/mL in Ora-Plus and Ora-Sweet Suspension
Author(s): Allen Loyd V Jr
Jan/Feb 2023
Pg. 52
Dapsone 2 mg/mL in Ora-Sweet and Ora-Plus
Author(s): Allen Loyd V Jr